Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Adecatumumab: Additional Phase II data

Additional data from a Phase II trial in 109 patients with EpCAM-positive metastatic breast cancer showed

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE